Compare Solaris Energy Infrastructure Inc. Class A Common Stock (SEI) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Solaris Energy Infrastructure Inc. Class A Common Stock vs BIO-TECHNE Corp — how do they compare? Solaris Energy Infrastructure Inc. Class A Common Stock trades at $68.36 (market cap $5.12B), while BIO-TECHNE Corp trades at $72.69 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 2.2× Solaris Energy Infrastructure Inc. Class A Common Stock's market cap, and Solaris Energy Infrastructure Inc. Class A Common Stock pays the higher dividend (0.62%). Which is the better fit depends on your goals — on Pluang, investors hold Solaris Energy Infrastructure Inc. Class A Common Stock for 0 Days and BIO-TECHNE Corp for 64 Days on average.
| SEI | TECH | |
|---|---|---|
Market Cap | $5.12B | $11.37B |
Volume | 2,532,496 | 2,420,565 |
Sector | Energy | Health |
52-Week High | $82.88 | $72.61 |
52-Week Low | $40.64 | $43.31 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $6.81B | $11.39B |
Dividend Yield | 0.62% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SEI (Solaris Energy Infrastructure) trades at $77.83, down 1.83% today, but maintains strong analyst support with 9 unanimous buy ratings and a $100.56 consensus price target. The stock shows positive momentum with three consecutive quarterly earnings beats and projected revenue growth from $622M in 2025 to $762M in 2026. Recent technical analysis indicates neutral signals with support at $76 and resistance at $79.
The outlook remains positive given strong earnings performance and expansion initiatives, though elevated valuation ratios (P/E of 98.52) and significant debt issuance ($1.25B notes) present risks. The upcoming Q3 2026 earnings report on October 21 will be crucial for validating growth trajectory amid energy sector volatility.
Bio-Techne (TECH) trades at $72.50, near its 52-week high of $72.70, with a slight daily decline of 0.08%. Technical indicators show a bullish trend, while valuation ratios like a P/E of 62.5 suggest premium pricing. Recent shareholder approval of the acquisition by Merck KGaA at $73.00 per share is a key development. Earnings have been mixed, with a beat in Q2 2026 but a miss in Q1 2026, and net income declined to $73.40 million in 2025 from $168 million in 2024.
The stock's outlook is supported by the pending acquisition, offering a near-term upside to the $73.00 buyout price. However, high valuation and earnings volatility pose risks. Analyst sentiment is balanced with 46% buy ratings, but no sell recommendations. Investors should weigh the acquisition premium against fundamental concerns like margin compression.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Solaris Energy Infrastructure Inc. Class A Common Stock
Solaris Energy Infrastructure, Inc. provides mobile power generation, control, and distribution equipment and logistics equipment for managing raw materials at well sites, operating through its Solaris Power Solutions and Solaris Logistics Solutions segments for data center, energy, commercial, and industrial customers.
Read more on SEI →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
